2020 IPO

Metacrine Stock

Metacrine is a privately held biotech company

Sign up today and learn more about Metacrine Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.



Notable Investors

ARCH Venture Partners


San Diego CA, US

Total Funding


About Metacrine Stock

Metacrine is a privately held biotech company 
founded in 2015 on technology licensed from the 
laboratory of Dr. Ronald Evans, a world leader in
 nuclear hormone receptors and Howard Hughes
Medical Institute Investigator at the Salk Institute. Metacrine will leverage two mechanistically distinct programs to target diabetes, steatohepatitis and other metabolic and liver disorders.


Funding History

August 2015$36.0M
December 2017$22.0M
June 2018$65.0M



Neil McDonnell


Trisha Millican

CEO & President

Ken Song


EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: